US 11819517
Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
granted A61KA61K2239/38A61K2239/57
Quick answer
US patent 11819517 (Methods of using tumor infiltrating lymphocytes in double-refractory melanoma) held by Iovance Biotherapeutics, Inc. expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Iovance Biotherapeutics, Inc.
- Grant date
- Tue Nov 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 15
- CPC classes
- A61K, A61K2239/38, A61K2239/57, A61K35/00, A61K40/11